Neuroscience Discovery & Alternatives to Opioids Speakers

BioOhio is proud to present an amazing line up of speakers, moderators, and panelists for Neuroscience Discovery & Alternatives to Opioids. Below you will find brief biographies and links to their respective organizations.

9:00 – Introduction & Opening Remarks

John F. Lewis, Jr., President & CEO, BioOhio

John F. Lewis, Jr., is a 4th generation Ohioan, his family tracing Ohio roots to the mid 1800s. He is a licensed attorney with experience in international business, venture capital investments and economic development. John is an outspoken advocate for industry led, market facing academic/industry collaborations. During the last 16+ years with BioOhio, John has helped raise nearly $1 billion for Ohio bioscience entities. He was a founding partner of the First Fifty Fund and Ohio TechAngel Fund both based in Columbus. John has more than 18 years international experience, lived in Jamaica, Korea and China, the latter two with Perkin Elmer, while traveling to more than 42 others. John is a graduate of Miami (Ohio) University and Capital University Law School.

9:10 – Keynote: The Landscape and Future of Neuroscience Discovery

Jill Schiaparelli, Chief Operating Officer, Neurotechnology Innovations Translator | CEO, Veressa Medical

Jill has more than 20 years of global experience in health care innovation, strategy and commercialization. She has launched multiple medical device and biotech products and has held senior leadership positions with major healthcare companies such as Johnson & Johnson and Baxter and has served as an executive at high-growth biotech companies such as ApaTech (UK) (sold to Baxter) and AxoGen. Jill currently serves as COO at Neurotechnology Innovations Translator, advising early stage start-ups in the neuroscience space. Jill is also a founding partner in JS Strategic Partners, a strategic consulting group to help young companies bring innovative technologies to market. Her early career was spent in investment banking and finance.

Joseph Broderick, MD, Professor of Neurology, Director, University of Cincinnati Gardner Neuroscience Institute

Joseph Broderick, MD, is the Director at the UC Gardner Neuroscience Institute, and has been a Neurologist with UC Physicians since 1987. Dr. Broderick became a professor of Neurology at the University of Cincinnati in 1996, and has been the Albert Barnes Voorheis Chair for the Department of Neurology at the UC College of Medicine since 2000. He has served as a courtesy staff member in 15 community hospitals for over 20 years, and is currently the principal investigator for the national coordinating center for StrokeNET, a network of 25 regional stroke centers. Dr. Broderick is an internationally recognized expert on the treatment and underlying causes of stroke. Dr. Broderick’s two-fold passion is to improve the treatment and outcome of stroke patients world-wide, using the Greater Cincinnati and Northern Kentucky region as a model, and to have world class patient care and research for all areas of neurologic disease at the University of Cincinnati Gardner Neuroscience Institute.

Ali Rezai, MD, Director, Rockefeller Neuroscience Institute; Associate Dean; John D. Rockefeller IV tenured professor in neuroscience, West Virginia University

Dr. Rezai is a board-certified neurosurgeon whose clinical areas of expertise include the neurosurgical and neuromodulation management of patients with Parkinson’s disease, dystonia, chronic pain, brain and spinal cord injuries, as well as severe mood and anxiety disorders. He will also serve as associate dean and the John D. Rockefeller IV tenured professor in neuroscience at the WVU School of Medicine. Rezai has been a significant leader in the novel and innovative use of brain implants for treating Parkinson’s disease, obsessive-compulsive disorder, Alzheimer’s disease, and traumatic brain injury. His work is recognized across the globe, and his research involving a brain-computer interface to treat paralysis was published in the journal Nature last year and also generated front-page news in The New York Times, The Wall Street Journal, and the Financial Times. He has also developed pioneering technologies that led to the creation of a company that produces micro-implants to treat chronic pain and headaches.

10:10 – Incubator and Investor Panel for Neuroscience Discovery

Jill Schiaparelli, Chief Operating Officer, Neurotechnology Innovations Translator | CEO, Veressa Medical

Jill has more than 20 years of global experience in health care innovation, strategy and commercialization. She has launched multiple medical device and biotech products and has held senior leadership positions with major healthcare companies such as Johnson & Johnson and Baxter and has served as an executive at high-growth biotech companies such as ApaTech (UK) (sold to Baxter) and AxoGen. Jill currently serves as COO at Neurotechnology Innovations Translator, advising early stage start-ups in the neuroscience space. Jill is also a founding partner in JS Strategic Partners, a strategic consulting group to help young companies bring innovative technologies to market. Her early career was spent in investment banking and finance.

Charles Steiner, Director, Business & Product Development | Innovations, Cleveland Clinic

Charles Steiner has over 25 years of experience in medical technology development. Prior to joining CCI, Charles was a product development engineer for the Center for Neurological Restoration and a business and technology developer for the Center for Minimally Invasive Surgery at Cleveland Clinic. His contributions have been in the field of surgical navigation for cranial and spinal indications, neuromodulation for movement and cognitive indications as well as neuromodulation for headache and autonomic indications. Charles received his BS in chemistry and computer science from Case Western Reserve University.

11:15 – Innovations that Impact Lives, the Future of Neuroscience (Research Focused)

Clay Marsh, MD, Vice President and Executive Dean Health Sciences, West Virginia University

Clay Marsh, MD, is West Virginia University’s chief health officer, and serves as a member of President E. Gordon Gee’s leadership team. As WVU’s vice president for health sciences, he oversees five health sciences schools and three health campuses, and serves on the governing boards that determine policy and priorities for WVU Medicine and its component organizations. In addition, as executive dean, he is the leader of the WVU School of Medicine. He is a two-time graduate of West Virginia University, earning an undergraduate degree in biology in 1981 and a medical degree in 1985.

Jonathan Cachat, Ph.D., Director of Laboratory Sciences Program, Hocking College; President & CEO, CCV Research

Over the last 4 years, Dr. Cachat raised and managed a $3.5M investment for the development of SunGrown Indoor cultivation system. Together, it represents a game-changer that provides multiple strategic advantages over competition. A result of his data-driven approach and business sensibility, Dr. Cachat is the exclusive distribution partner of DSS systems for the indoor agricultural/cultivation market worldwide. Dr. Cachat has a doctorate degree in Neuroscience, focusing on Psychopharmacology. He has published over 50 peer-reviewed scientific articles and 2 books on the use of adult zebrafish in behavioral pharmacology research. Dr. Cachat is also specialized in Data Science, working at the University of California, San Diego and the University of California, Davis on big-data neuroscientific data integration platforms.

1:15 – Keynote Fireside Chat: Investing in Community Addiction Recovery

Moderated by Phyllis Grauer, PharmD, BCGP, CPE, CDCA, Owner, Specialty Practice Clinical Consultant, ChaRxis Consulting

Phyllis Grauer, PharmD has been a pain, palliative care and hospice clinical pharmacist for more than 30 years. She received her BPharm from The Ohio State University and her PharmD from Kansas University. Phyllis is a Certified Pain Educator (CPE), is Board Certified in Geriatric Pharmacy (BCGP) and a Chemical Dependency Counselor Assistant (CDCA). She founded a nationwide hospice and palliative care clinical consulting company, has lectured extensively and has taught at Ohio State University, Cedarville University, Ohio Northern University and University of Findlay Schools of Pharmacy and has multiple publications. She provides educational programs, patient specific consultation in the areas of pain and symptom medication management, geriatric pharmacotherapy, palliative care, medication therapy reconciliation and management and risk assessment and management of substance use disorder.

Ben Ertel, Business Development, Hotel California by the Sea | Board Member, The Ohio Citizen Advocates for Addiction Recovery

Ben went to the University of Cincinnati where he majored in Political Science and began actively volunteering on several political campaigns. Ben was a staff assistant in Washington DC for a member of the U.S. House of Representatives and in 2008, Ben was a volunteer coordinator for a presidential campaign. Prior to getting sober, Ben struggled to find the type of treatment program he needed to gain the tools necessary for life-long recovery. Eventually, through legal consequences, Ben was mandated to complete addiction treatment through the Hamilton County Drug Court. Today, Ben credits his lasting sobriety to their long-term continuum of care. Combining his prior experience and his own recovery, Ben’s passion lies in advocacy and helping others access quality treatment. Joining Hotel California by the Sea Cincinnati as a business development and admissions representative, he is excited to bring a proven dual diagnosis treatment program to the Cincinnati area.

Benjamin Glassman, United States Attorney, Southern District of Ohio

Benjamin C. Glassman serves as the United States Attorney for the Southern District of Ohio by appointment of the court. An Assistant United States Attorney since 2005, Mr. Glassman has previously been the district’s Acting United States Attorney, First Assistant, Appellate Chief, Acting Criminal Chief, Professional Responsibility Officer, and Reentry and Prevention Coordinator. He has argued more than one hundred cases before the United States Court of Appeals for the Sixth Circuit and has tried multiple cases to verdict. Mr. Glassman holds a B.A., magna cum laude, from Rice University and a J.D., magna cum laude, from Harvard Law School. Mr. Glassman serves on the Terrorism and National Security Subcommittee of the Attorney General’s Advisory Committee and is a member of the Department of Justice’s Opioid & Heroin and Health Care Fraud Working Groups, the interagency Domestic Terrorism Executive Committee, and the executive board of the Ohio High Intensity Drug Trafficking Area.

Randy Jernejcic, MD, MMM, Vice President of Clinical Integration, University Hospitals, First Physician Chair, Northeast Ohio Hospital Opioid Consortium

Randy Jernejcic M.D. is the newly appointed Vice President of Clinical Integration for University Hospitals of Cleveland. Previously, he was the chief medical officer for University Hospitals Ahuja Medical Center and Interim Director, UH Pain Institute, University Hospitals. He will continue as the Chair of the Opioid Patient Safety Steering Committee at University Hospitals. Dr. Jernejcic is also the Physician Chair of the Northeast Ohio Hospital Opioid Consortium. He is Board Certified in Family Medicine and is a graduate of The Ohio State University for both his undergraduate degree in Mathematics and medical school. He completed his residency program in Family Medicine at OhioHealth Grant Medical Center and has twenty years of clinical experience in both primary care and emergency medicine as well as ten years of executive physician leadership.

Sarah Nerad, MPA, Associate Director of Community Relations, Alkermes

As an addiction treatment and recovery advocate, Sarah Nerad is dedicated to advancing behavioral health systems to ensure successful long-term outcomes for people with substance use disorder. Sarah currently serves as the Associate Director of Community Relations for Alkermes. Prior to her work at Alkermes, Sarah worked at The Ohio State University for over four years with the Collegiate Recovery Community and the Higher Education Center for Alcohol and Drug Misuse Prevention and Recovery. Sarah’s current passion project is serving as a founding board member of Heartland High School, a recovery high school in central Ohio.

2:15 – Pain Management: Alternatives to Opioids

Moderated by Solomon Wilcots, Former Cincinnati Bengal | Radio Talk Show Host at Sirius XM Inc.| NFL Analyst at Sky Sports UK | Leader of Sports/Health public relations initiatives at Russo Partners Sports – Health Alliance

Solomon Wilcots career started as a defensive end on the Cincinnati Bengals. He played for four seasons with the Bengals (1987-90), one with the Vikings (1991) and finished six-year career with the Steelers (1992). Since retiring from the NFL Wilcots has worked as a sideline reporter at ESPN, a game analyst at CBS Sports, and a studio analyst at NFL Network. Wilcots joined Russo Partners in 2017 as a Team Leader for the newly formed Sports-Health Division overseeing PR initiatives for many bio-membered companies. During his 2 years with Russo Partners, Wilcots has led initiatives to enroll patients in clinical trials, and he has created educational based video content to highlight innovative technologies and treatments for Bio Tech and Big Pharma.

Gregory Fiore, MD, President and Chief Executive Officer, Sollis Therapeutics

Dr. Fiore is an entrepreneur and founder of two successful healthcare consulting firms, Fiore Healthcare Advisors and SSI Strategy. Dr. Fiore was previously the Chief Medical Officer of The Medicines Company, a global, commercial-stage biopharmaceutical company focused on hospital products. Dr. Fiore previously worked as a Strategy Consultant at McKinsey & Company and has held executive roles in several pharmaceutical / biotechnology companies such as Merck, The Medicines Company, and Abbott Laboratories. Dr. Fiore received medical training at Harvard Medical School’s Brigham and Women’s Hospital and Pulmonary / Critical Care training in the Harvard Medical School Pulmonary and Critical Care Fellowship Program. He received his MD degree and was valedictorian at New York Medical College and received a B.S. degree in Zoology from the University of Rhode Island with honors.

Chandu Kasibhatla, PhD, MBA, Associate Director, Medical Affairs, US WorldMeds

Chandu has over 20 years of experience in the pharmaceutical industry.  He started his career at Procter & Gamble Pharmaceuticals in drug discovery research. Over the course of his career, Chandu led various projects with increasing responsibilities.  He worked in several therapeutic areas including women’s health, gastroenterology, urology, immunology and opioid withdrawal management.  His experience spans medical affairs, drug discovery research, business development, financial analysis and strategic planning.  Chandu received his Ph. D. from the Indian Institute of Science, Bangalore, India and his MBA from Xavier University in Cincinnati, OH.

Adam Link, Director, Pain Management Therapy Development, AtriCure

Adam joined AtriCure in October 2015 leading global marketing efforts related to the concomitant open cardiac surgical ablation market. He recently took on new responsibilities within Atricure to lead therapy development efforts for post-operative pain management in cardiothoracic surgery. Prior to AtriCure, Adam held a variety of leadership roles within marketing and sales at St. Jude Medical and Boston Scientific. Adam holds a B.S. in Business from the Kelley School of Business at Indiana University.

Brad Pulver, President, Innovative Medical Equipment

Brad has co-founded and managed two startup medical device companies – one still in early development and FDA Approval stage, the other generating positive cash flow. He has led all phases of medical device company and product lifecycle – capital raising, conceptualization, product design and development, regulatory approval, manufacturing & supply chain, sales and marketing, domestic & international business development, distribution, customer service, P&L management responsibility, development of strategic partnerships. He is the recipient of an Ohio Third Frontier CALF loan, Opioid Grant and NIH Grant monies. He received his BS in Applied Economics and Business Management from Cornell University and an MBA from The Wharton School, University of Pennsylvania.

Jon Snyder, Founder, Chief Business Officer, Neuros Medical

Jon Snyder is the Founding President and CEO of Neuros Medical, Inc., a Cleveland, Ohio based neuromodulation company focused on developing proprietary therapies for unmet needs to patients worldwide. He holds over 20 years of global management experience in biomedical and healthcare sales, marketing, and operations with significant experience in bringing new products into the marketplace. His background covers business development, product development, market management, sales management, venture capital investment, and fundraising at start-up and Fortune 500 (Top 20) companies including Cyberonics, Cardinal Health, Imalux, and STERIS. Snyder has a B.S. from Ohio University.